← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
101	101 DELISTED Generation Bio GBIO	–	–	–	–
102	102 CytoMed Therapeutics GDTC $10M	–	–	–	–
103	103 Guardant Health GH $22.4B	–	–	–	–
104	GMDA 104 DELISTED Gamida Cell Ltd. Ordinary Shares GMDA	–	–	–	–
105	105 Corgi Genomics & Precision Medicine ETF GNMX $1.67M	–	–	–	–
106	106 Global X Genomics & Biotechnology ETF GNOM $99.3M	–	–	–	–
107	107 Genprex GNPX $1.93M	–	–	–	–
108	108 Genenta Science GNTA $32.5M	–	–	–	–
109	109 GRAIL Inc GRAL $6.16B	–	–	–	–
110	GRCL 110 DELISTED Gracell Biotechnologies Inc. American Depositary Shares GRCL	–	–	–	–
111	GRML 111 Greenland Mines Ltd GRML $85.3M	–	–	–	–
112	GTH 112 DELISTED Genetron Holdings Limited ADS GTH	–	–	–	–
113	113 Fractyl Health GUTS $54.8M	–	–	–	–
114	114 Franklin Genomic Advancements ETF HELX $29.8M	–	–	–	–
115	HTGM 115 DELISTED HTG Molecular Diagnostics, Inc. Common Stock HTGM	–	–	–	–
116	116 iShares Genomics Immunology and Healthcare ETF IDNA $318M	–	–	–	–
117	117 Immix Biopharma IMMX $722M	–	–	–	–
118	118 Immatics IMTX $1.08B	–	–	–	–
119	119 IN8bio INAB $11.7M	–	–	–	–
120	120 MiNK Therapeutics INKT $51M	–	–	–	–
121	121 INmune Bio INMB $46.1M	–	–	–	–
122	122 Century Therapeutics IPSC $270M	–	–	–	–
123	KRBP 123 DELISTED Kiromic BioPharma, Inc. Common Stock KRBP	–	–	–	–
124	124 Korro Bio KRRO $140M	–	–	–	–
125	125 Krystal Biotech KRYS $9.81B	–	–	–	–